secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2026-05-26T10:09:56+00:00
Accession:  0001104659-26-065908
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EDIT-401 preclinical data shows ~90% mean reductions in LDL-C, Lp(a), ApoB in NHPs
--------------------------------------------------------------------------------

- Single dose achieved ≥90% mean reduction in LDL-C, rapid and dose-dependent, durable through 6 months in NHPs.
- Achieved ~90% mean reduction in Lp(a) and ApoB, supporting unified LDLR upregulation mechanism.
- Well-tolerated at therapeutically relevant dose 1.5 mg/kg; no adverse observations in ongoing GLP toxicology.
- Plans to submit CTN in Australia by mid-2026; first-in-human HeFH trial later in 2026; early human PoC data by end of 2026.
- Received positive pre-IND feedback from FDA on nonclinical package, CMC plans, and study design.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000110465926065908/0001104659-26-065908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000110465926065908/tm2615565d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-065908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer